Docket No.: PB60300

[X]

DECLARATION

As a below named inventor, I hereby declare that:

the specification of which (check one)

[] is attached hereto.

was filed on 13 August 2004

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

" ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR "

as Serial No. PCT/GB2004/003516

and was ar	nended on	(if ap	plicable).	
_	I have reviewed and u ended by any amendme		f the above identified specification, includi	ng
_	e duty to disclose informategulations, Section 1.5		to the patentability as defined in Title 37,	
of any foreign app application which identified below a	olication(s) for patent o designated at least one my foreign application	r inventor's certificate, or country other than the U	ates Code, Section 119(a)-(d) or Section 36 r Section 365(a) of any PCT International United States, listed below and have also sertificate, or PCT International application ty is claimed.	
Prior Foreign App	olication(s)			
Number	Country	Filing Date	Priority Claimed	
0319126.9	GB	14 August 2003	YES .	
I hereby claim the application(s) liste		, United States Code, Sec	ction 119(e) of any United States provision	ıal
Application Numbe	r Filing Date			
Section 365(c) of the subject matter International appl 112, I acknowledg Code of Federal R	any PCT International of each of the claims of ication in the manner page the duty to disclose its legulations, Section 1.5	application designating to this application is not or rovided by the first paraginformation which is mat	ction 120 of any United States application(the United States, listed below and, insofar disclosed in the prior United States or PCT graph of Title 35, United States Code, Sect terial to patentability as defined in Title 37, the between the filing date of the prior is application.	as
Scriai IVO.	Filling Date	Status		

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Matthew CAMPBELL

Inventor's Signature: M. Lungh

Residence:

STEVENAGE, HERTFORDSHIRE, GB

Citizenship:

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Richard Jonathan HATLEY

Inventor's Signature:

Residence:

STEVENAGE, HERTFORDSHIRE, GB

Citizenship:

GB

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor	: Jag Paul HEER
Inventor's Signature:_	$\overline{1}$
Date: NST Am	1206
Residence: HARI	LOW, ESSEX, GB
Citizenship: GB	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939
	Andrew McMurtrie MASON
Inventor's Signature:_	Andre Masa
Date: 12 Ap	
Residence: STEV	ENAGE, HERTFORDSHIRE, GB
Citizenship: GB	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939
Full Name of Inventor	r: Ivan Leo PINTO
Inventor's Signature:_	low he lit
Date: 21ex 19px	12000
Residence: STEV	ENAGE, HERTFORDSHIRE, GB
Citizenship: GB	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939

.:

Full Name of Invento	r: Shahzad Sharooq RAHMAN
Inventor's Signature:_	- fleet
Date: 2//4/	06
Residence: HAR	LOW, ESSEX, GB
Citizenship: GB	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939
	r: Ian Edward David SMITH
Inventor's Signature:_	
Date: 12/4	106
Residence: STEV	ENAGE, HERTFORDSHIRE, GB
Citizenship: GB	
Post Office Address:	GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, Pennsylvania 19406-0939

.

.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/GB2004/003516	
Filing Date	13 August 2004	
First Named Inventor	Matthew CAMPBELL	
Title	ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR	
Art Unit		
Examiner Name		
Attorney Docket Number	PB60300	

Practitioners associated with the Customer Number	pers. 20462		
Or	E15. 20402		
☐ Practitioner(s) named below:			
Name	Registration Number		
Name	registration rumber		
As my/our attorney(s) or agent(s) to prosecute the applic	cation identified above, and to transact all business in the		
United States Patent and Trademark Office connected therewith.			
Please recognize or change the correspondence address f	for the above-identified application to:		
☐ The address associated with the above-mentioned Customer Number:			
Or			
■ The address associated with Customer Number 20	0462		
Or			
☐ Firm or Individual Name:			
Address:			
Address:			
City:	State: Zip:		
Country:			
Telephone:	Fax:		
I am the:			
Applicant/Inventor:			
Assignee or reford of the entire interest. See 37 CFR 3.71.			
Statement until CFR 3.73(b) is enclosed. (F			
	Applicant or Assignee of Record		
Signature:	Date: 0 2 MAY 2006		
Name: Peter John GIDDINGS	Telephone: +44 20 8047 4414		
Title and Company: Attorney and Authorised Official, SmithKline Beecham Corporation			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			
*Total of: forms are submitted.	micu, see delow.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37	CRF 3.73(b)	
Applicant/Patent Owner: SmithKline Beecham Corporation		
International Application No./Patent No.: PCT/GB2004/003516 Fil		
Entitled: ANTHRANILIC ACID DERIVATIVES AND THEIR US	E AS ACTIVATORS OF THE HM74A RECEPTOR	
SmithKline Beecham Corporation, a corporation, states that it is:		
1. E the assignee of the entire right, title, and interest, or		
2. \square an assignee of less than the entire right, title and interest.		
The extent (by percentage) of its ownership interest is%	in the patent application/patent identified above	
by virtue of either;		
A. [] An assignment from the inventor(s) of the patent application		
recorded in the United States Patent and Trademark Office	at Reel, Frame, or for which a	
copy thereof is attached. OR		
OK .		
B. [] A chain of title from the inventor(s), of the patent application	on/patent identified above to the current assignee	
as shown below:	no parent recitation above, to the entrem assignee	
1. From: To:		
The document was recorded in the United States Paten	t and Trademark Office at	
Reel , Frame	or for which a copy thereof is attached.	
2. From: To:	, or for which a copy thereof is attached.	
The document was recorded in the United States Paten	t and Trademark Office at	
	, or for which a copy thereof is attached.	
3. From: To:		
The document was recorded in the United States Paten	t and Trademark Office at	
Reel, Frame	, or for which a copy thereof is attached.	
[] Additional documents in the chain of title are listed on	a supplemental sheet.	
[X] Copies of assignments or other documents in the chain of title are a		
[NOTE: A separate copy (i.e., a true copy of the original assignment		
Division in accordance with 37 CRF Part 3, if the assignment is to b	e recorded in the records of the USPTO.	
See MPEP 302.08]		
The undersigned (whose title is supplied below) is authorized to act on b	ehalf of the assignee.	
L LIV VI A)		
HHY NXI),	0 2 MAY 2006	
Signature	Date	
Peter John CIDDINGS	±44.20.8047.4414	
Peter John GIDDINGS +44 20 8047 4414 Printed or Typed Name Telephone Number		
Timed of Typed Name	rerephone reamoer	
Attorney and Authorised Official		
Title		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/WE, Matthew CAMPBELL, Richard Jonathan HATLEY, Andrew McMurtrie MASON, Ivan Leo PINTO and Ian Edward David SMITH of Stevenage, Hertfordshire GB and Jag Paul HEER and Shahzad Sharooq RAHMAN of Harlow, Essex, GB (hereinafter called "the inventor(s)") have invented or discovered "ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR" (hereinafter called "the invention") for which a patent application No. 0319126.9 was filed on 14 August 2003 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/GB2004/003516 filed 13 August 2004)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

whereas smithkline Beecham corporation organised and existing under and by virtue of the laws of the State of Pennsylvania and having its principal place of business at One Franklin Plaza, P O Box 7929, o:\ipd\ms\USASS1

Philadelphia, Pennsylvania 19101-7929, USA, is desirous of acquiring from **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES UNLIMITED of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND **DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to SMITHKLINE BEECHAM CORPORATION its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE SERVICES UNLIMITED and **GLAXOSMITHKLINE** RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom in the United States of America be issued to SMITHKLINE BEECHAM CORPORATION.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all

other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **SMITHKLINE BEECHAM CORPORATION**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 14 August 2003 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

M / IM

SIGNED by Mattnew CAMPBELL:
Date: 12/4/06
SIGNED by Richard Jonathan HATLEY: Date:
SIGNED by Jag Paul HEER: Date: 21 St April 2006
SIGNED by Andrew McMurtrie MASON: Andrew Mas C
Date: 12 April 06

SIGNED by Ivan Leo PINTO:
Date: 214 April 2006
SIGNED by Shahzad Sharooq RAHMAN: Date: 21/4/06
SIGNED by lan Edward David SMITH:
SIGNED by Peter John GIDDINGS as the Attorney of each of GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED:
0 2 MAY 2006 Date: